Help protect patients where they may want
to go with VAXCHORA
Videos & Resources
VAXCHORA Materials
Explore the World. Protect Your Health (Patient Guide)
A guide to help your patients stay healthy while traveling abroad
Download
Know the Risks of Cholera (Patient Brochure)
Explains the potential risks of cholera and answers frequently asked questions
Download
VAXCHORA “How to Reconstitute” Guide (HCP Resource)
How to prepare, reconstitute, and administer VAXCHORA
DownloadE-Learning Modules
Explore short video modules on travel health topics
Introduction to Cholera: Disease, Epidemiology, and Case Study
Role in Prevention
Important Safety Information
Contraindications
Do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine.
Indication and Usage
VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.
Limitations of Use: The effectiveness of VAXCHORA has not been established in persons living in cholera-affected areas. The effectiveness of VAXCHORA has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. VAXCHORA has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.
Important Safety Information
Warnings and Precautions
Altered Immunocompetence: The safety and effectiveness of VAXCHORA have not been established in immunocompromised persons and the immunologic response to VAXCHORA may be diminished.
Shedding and Transmission: Because VAXCHORA may be shed in the stool of recipients for at least 7 days and the vaccine strain can potentially be transmitted to non-vaccinated close contacts (e.g., household contacts), use caution when considering whether to administer VAXCHORA to individuals with immunocompromised close contacts.
Adverse Reactions
The most common adverse reactions (incidence > 3%) were tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%) and diarrhea (4%).
Drug Interactions
Antibiotics: Avoid concomitant administration of VAXCHORA with oral systemic antibiotics since these agents may be active against the vaccine strain. Do not administer VAXCHORA to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
Antimalarial Prophylaxis: Immune responses to VAXCHORA may be diminished when administered concomitantly with chloroquine. Administer VAXCHORA at least 10 days before beginning chloroquine.
Immunosuppressive Treatments: Immunosuppressive therapies may reduce the immune response to VAXCHORA.
VAX FULL HCP ISI 01/2021
Please see full Prescribing Information.References:
- Vaxchora [package insert], 12/2020; Emergent Travel Health Inc.
- Clinical update: cholera vaccine for travelers. Centers for Disease Control and Prevention. Updated March 10, 2020. Accessed March 20, 2020.
https://wwwnc.cdc.gov/travel/news-announcements/cholera-vaccine-for-travelers - Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016;62(11):1329-1335.
- McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. Vaccine. 2018;36(6):833-840.
Important Safety Information
Contraindications
Do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine.
More